Live Webinar

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Hosted by AJMC and Targeted Oncology

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image

Karen M. Clements, ScD

Articles by Karen M. Clements, ScD

Cost-Benefit Analysis of Sacubitril/Valsartan in a Medicaid Population

ByAlan Gabot, PharmD,Pavel Lavitas, PharmD, BCPS,Rachel Bacon, PharmD, MPH,Thomas C. Pomfret, PharmD, MPH, BCPS,Mckenzie Taylor, PharmD, MS,Andrew Coelho, PharmD,Bonnie C. Greenwood, PharmD, BCPS,Caroline J. Alper, MD,Karen M. Clements, ScD,Kimberly Lenz, PharmD, MBA

The cost avoidance of heart failure–related hospitalizations and emergency department visits may outweigh the additional drug cost in Medicaid members adherent to sacubitril/valsartan.

Evaluating Proactive Outreach for Prior Authorization Recertifications in Medicaid Patients

BySoumya Vishwanath, PharmD,Stephanie N. Tran, PharmD, BCPS,Thomas C. Pomfret, PharmD, MPH, BCPS,Kaelyn C. Boss, PharmD,Mark Tesell, PharmD, BCPS,Mylissa Price, MPH, RPh,Caroline J. Alper, MD,Lorean Muchnik, RPh,Karen M. Clements, ScD,Kimberly Lenz, PharmD

Implementing a proactive provider outreach program resulted in significantly more prior authorization recertifications and a reduction in time to submission.

Latest Updated Articles